Related Experiment Video
Updated: Jul 2, 2026

A Comprehensive Pipeline to Assess the Efficiency of Human Erythropoiesis In Vitro and Ex Vivo
Published on: January 10, 2025
Hematide, a novel peptide-based erythropoiesis-stimulating agent for the treatment of anemia
1King's College Hospital, Renal Unit, Denmark Hill, London SE5 9RS, UK. Iain.Macdougall@kch.nhs.uk
Hematide is a synthetic peptide-based erythropoiesis-stimulating agent that is being developed by Affymax Inc and Takeda Pharmaceutical Co Ltd. Hematide is undergoing phase III clinical trials for anemia.
Hematide is a synthetic peptide-based erythropoiesis-stimulating agent that is being developed by Affymax Inc and Takeda Pharmaceutical Co Ltd. Hematide is undergoing phase III clinical trials for anemia.
Related Concept Videos
Erythropoiesis
Erythropoiesis
Role of Hematopoietic Growth Factors
Thrombopoietin (TPO), mainly released by the liver,...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Factors Affecting Erythropoiesis
Several factors influence the erythrocyte production rate, with tissue oxygen level being among the most critical. Intense exercise or high altitudes can cause tissue hypoxia, which triggers the kidneys to release more erythropoietin (EPO) into the bloodstream.
EPO then...
Hemoglobin
When all four heme groups are bound to oxygen, the resulting molecule is called oxyhemoglobin. As a result, arterial blood...
